^
    Back
    Association details:
    Biomarker:TMB-L
    Cancer:Malignant Pleural Mesothelioma
    Drug Class:PD-L1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Treat Res
    Title:

    Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes

    Published date:
    11/03/2020
    Excerpt:
    Median PFS with immunotherapy was poor with at 1.5 months (SD ±0.4). Overall PDL1 expression and TMB is low in patients with MPM resulting in limited benefit from single agent PD-1/PD-L1 agent.
    DOI:
    10.1016/j.ctarc.2020.100232